4 hours Ago By ABMN Staff
AstraZeneca PLC ( LON:AZN – Get Free Report ) has earned an average rating of “Moderate Buy” from the nine brokerages that are covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and six have issued a buy recommendation on the company.
The average 1-year price target among brokers that have issued a report on the stock in the last year is GBX 7,935.67 ($98.40).
Several research firms have issued reports on AZN. Berenberg Bank restated a “buy” rating and set a GBX 140 ($1.74) price objective on shares of AstraZeneca in a report on Monday, January 27th.
JPMorgan Chase & Co. restated an “overweight” rating and issued a £140 ($173.59) target price on shares of AstraZeneca in a report on Friday, November 22nd.
Finally, Shore Capital reiterated a “buy” rating on shares of AstraZeneca in a report on Thursday, November 7th. Get Our Latest Report on AstraZeneca AstraZeneca Price Performance Insiders Place Their Bets In related news, insider Tony Mok acquired 1,500 shares of the company’s stock in a transaction on Tuesday, November 19th. The stock was purchased at an average cost of £126.
80 ($157.22) per share, with a total value of £190,200 ($235,833.85).
Also, insider Pascal Soriot bought 20,000 shares of the firm’s stock in a transaction on Thursday, November 14th. The stock was acquired at an average price of £102.03 ($126.
51) per share, for a total transaction of £2,040,600 ($2,530,192.19). Corporate insiders own 0.
04% of the company’s stock. AstraZeneca Company Profile ( Get Free Report AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Further Reading Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.
com's FREE daily email newsletter ..
